With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line …

Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately
20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or …

MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to
modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have …

PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML)
receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …

Alzheimer’s disease is a severe neuron disease that damages brain cells which leads to
permanent loss of memory also called dementia. Many people die due to this disease every …

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function 1 , 2 – 3 . The interaction of menin with lysine methyltransferase …

Background Venetoclax combined with hypomethylating agents is a new standard of care
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or older, …

… Osorio, and G. Lefranc, ‘‘SVM and ANN application to multivariate pattern recognition using
… ISSA received the MS and Ph.D. degrees in computer science/artificial intelligence from Old …

Background Ponatinib and blinatumomab are effective therapies in patients with Philadelphia
chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their combination …